Answers are grounded in this paper and cite their sources.
Kidney transplantation is the gold standard treatment for end-stage kidney disease. Despite increasing transplant case volume in recent years, its access is limited due to a donor organ shortage, resulting in significant waitlist mortality. Xenotransplantation has the potential to address this unmet need and has made significant progress from early, largely unsuccessful nonhuman-primate experiments in the 1960s to early clinical application in the 2020s: genetically modified pig kidneys have now provided dialysis-independent function in a few living human recipients, sustained for months in some cases. These clinical experiences, together with preclinical nonhuman-primate data, demonstrate that genetically modified pig kidneys can achieve meaningful short-term renal replacement. However, graft durability remains a challenge partly due to immunologic rejection, complement activation, and infection. Given these limitations, kidney xenotransplantation cannot yet be considered a routine alternative to human kidney transplantation. We argue that, at its current stage, it is most appropriately positioned as an investigational rescue strategy for carefully selected patients who face high mortality risk on dialysis and a low likelihood of timely allotransplantation, and that its clinical value should be benchmarked against the expected longevity of high-Kidney Donor Profile Index allografts rather than judged against optimal human kidneys alone. Continued advances in genetic engineering, immunosuppression, and post-transplant monitoring may allow xenotransplantation to approach outcomes comparable to allotransplantation over time, though whether and when this will occur remains uncertain.
No takes yet. Share an insight, caveat, or question.
Yokota et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: